Trial Profile
A real life compassionate use program evaluating efficacy and safety of Osimertinib in patients with lung cancer
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 10 Nov 2017
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Lung cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer